Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Amyloid documented by biopsy.~2. Documented V30M TTR mutation.~3. Peripheral and/or autonomic neuropathy with a Karnofsky Performance Status ≥50.~4. Patient is 18-75 years old.~5. If female, patient is post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control. If male with a female partner of childbearing potential, willing to use an acceptable method of birth control for the duration of the study. For both females and males, birth control must be used for at least 3 months after the last dose of study medication.~6. Patient is, in the opinion of the investigator, willing and able to comply with the study medication regimen and all other study requirements.~Exclusion Criteria:~1. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs).~2. Primary amyloidosis.~3. If female, patient is pregnant or breast feeding.~4. Prior liver transplantation.~5. No recordable sensory threshold for vibration perception in both feet, as measured by CASE IV.~6. Positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV), and/or human immunodeficiency virus (HIV).~7. Renal insufficiency or liver function test abnormalities.~8. New York Heart Association (NYHA) Functional Classification ≥III.~9. Other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic inflammatory diseases).~10. Co-morbidity anticipated to limit survival to less than 18 months.~11. Patient received an investigational drug/device and/or participated in another clinical investigational study within 60 days before Baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1. (Type: EXPERIMENTAL): Fx-1006A
- 2. (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).